Protalix Historical Balance Sheet

PLX Stock

USD 2.58 0.10 4.03%

Trend analysis of Protalix Biotherapeutics balance sheet accounts such as Non Current Assets Total of 9.8 M, Cash And Short Term Investments of 33.8 M, Net Receivables of 3.1 M or Common Stock Shares Outstanding of 85.1 M provides information on Protalix Biotherapeutics' total assets, liabilities, and equity, which is the actual value of Protalix Biotherapeutics to its prevalent stockholders. By breaking down trends over time using Protalix Biotherapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Protalix Biotherapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Protalix Biotherapeutics is a good buy for the upcoming year.

Protalix Biotherapeutics Inventory

22.31 Million

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protalix Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.

About Protalix Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Protalix Biotherapeutics at a specified time, usually calculated after every quarter, six months, or one year. Protalix Biotherapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Protalix Biotherapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Protalix currently owns. An asset can also be divided into two categories, current and non-current.

Protalix Biotherapeutics Balance Sheet Chart

At this time, Protalix Biotherapeutics' Short Term Investments are fairly stable compared to the past year. Inventory is likely to rise to about 22.3 M in 2025, whereas Total Assets are likely to drop slightly above 52.1 M in 2025.

Total Assets Total Current Liabilities Non Current Assets Total Cash And Short Term Investments

Add Fundamental

Total Assets

Total assets refers to the total amount of Protalix Biotherapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Protalix Biotherapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Protalix Biotherapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Protalix Biotherapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Non Current Assets Total

The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Protalix Biotherapeutics balance sheet. This account contains Protalix Biotherapeutics investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Protalix Biotherapeutics fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Most accounts from Protalix Biotherapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Protalix Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protalix Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.At this time, Protalix Biotherapeutics' Short Term Investments are fairly stable compared to the past year. Inventory is likely to rise to about 22.3 M in 2025, whereas Total Assets are likely to drop slightly above 52.1 M in 2025.

	2022	2023	2024	2025 (projected)
Non Current Assets Total	10.9M	14.5M	13.3M	9.8M
Cash	17.1M	23.6M	19.8M	31.4M

Non Current Assets Total Cash

Protalix Biotherapeutics balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Net Debt	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Total Liab	Total Current Assets	Short Long Term Debt Total	Total Stockholder Equity	Property Plant And Equipment Net	Retained Earnings	Non Currrent Assets Other	Common Stock Total Equity	Other Stockholder Equity	Short Term Debt	Common Stock	Accounts Payable	Short Term Investments	Other Assets	Other Liab
Total Assets		0.05	0.25	-0.21	0.82	0.57	0.94	-0.03	0.04	0.41	-0.64	0.54	0.99	0.52	0.05	0.46	-0.23	-0.17	0.48	0.41	0.5	0.56	0.09	0.06	0.33	0.21
Other Current Liab	0.05		0.32	0.06	-0.26	0.34	-0.14	0.5	0.54	-0.33	-0.28	-0.11	-0.01	-0.24	0.24	0.33	-0.43	0.08	-0.46	0.32	0.18	-0.38	0.11	0.5	-0.34	-0.15
Total Current Liabilities	0.25	0.32		0.58	-0.06	0.22	0.13	0.04	0.13	-0.27	-0.42	0.26	0.23	0.34	-0.16	0.13	-0.44	-0.14	-0.07	0.21	0.67	-0.05	0.2	0.32	-0.1	-0.24
Net Debt	-0.21	0.06	0.58		-0.31	-0.34	-0.24	0.12	-0.04	-0.06	-0.29	0.23	-0.16	0.12	-0.45	-0.43	-0.34	-0.25	-0.25	0.2	0.21	-0.28	-0.06	0.08	0.05	-0.47
Cash	0.82	-0.26	-0.06	-0.31		0.32	0.95	-0.32	-0.37	0.65	-0.36	0.64	0.84	0.64	-0.14	0.31	0.19	-0.09	0.7	0.08	0.39	0.65	-0.03	-0.29	0.58	0.37
Non Current Assets Total	0.57	0.34	0.22	-0.34	0.32		0.4	0.42	0.1	0.26	-0.29	0.38	0.43	0.48	-0.06	0.97	-0.26	0.45	0.16	0.23	0.24	0.22	0.66	0.05	0.15	0.56
Cash And Short Term Investments	0.94	-0.14	0.13	-0.24	0.95	0.4		-0.27	-0.18	0.5	-0.47	0.58	0.95	0.6	-0.01	0.34	0.04	-0.16	0.62	0.22	0.52	0.63	-0.04	-0.14	0.39	0.25
Net Receivables	-0.03	0.5	0.04	0.12	-0.32	0.42	-0.27		0.42	0.03	-0.29	0.06	-0.12	-0.08	-0.09	0.35	-0.6	0.36	-0.14	0.38	-0.27	-0.02	0.53	0.22	0.03	0.11
Common Stock Shares Outstanding	0.04	0.54	0.13	-0.04	-0.37	0.1	-0.18	0.42		-0.63	-0.43	-0.48	0.03	-0.67	0.71	0.02	-0.71	-0.28	-0.39	0.68	-0.18	-0.18	-0.07	0.66	-0.59	-0.53
Non Current Liabilities Total	0.41	-0.33	-0.27	-0.06	0.65	0.26	0.5	0.03	-0.63		-0.16	0.84	0.4	0.66	-0.72	0.26	0.18	0.15	0.57	-0.07	0.04	0.47	0.21	-0.51	0.81	0.7
Other Current Assets	-0.64	-0.28	-0.42	-0.29	-0.36	-0.29	-0.47	-0.29	-0.43	-0.16		-0.43	-0.65	-0.16	-0.01	-0.15	0.77	0.51	-0.13	-0.73	-0.22	-0.24	0.01	-0.28	-0.28	0.23
Total Liab	0.54	-0.11	0.26	0.23	0.64	0.38	0.58	0.06	-0.48	0.84	-0.43		0.52	0.81	-0.76	0.36	-0.11	0.05	0.56	0.11	0.39	0.45	0.32	-0.31	0.73	0.56
Total Current Assets	0.99	-0.01	0.23	-0.16	0.84	0.43	0.95	-0.12	0.03	0.4	-0.65	0.52		0.47	0.07	0.32	-0.2	-0.28	0.49	0.41	0.5	0.57	-0.04	0.06	0.33	0.12
Short Long Term Debt Total	0.52	-0.24	0.34	0.12	0.64	0.48	0.6	-0.08	-0.67	0.66	-0.16	0.81	0.47		-0.65	0.47	0.18	0.28	0.59	-0.13	0.46	0.47	0.4	-0.44	0.65	0.54
Total Stockholder Equity	0.05	0.24	-0.16	-0.45	-0.14	-0.06	-0.01	-0.09	0.71	-0.72	-0.01	-0.76	0.07	-0.65		-0.06	-0.1	-0.22	-0.28	0.27	-0.13	-0.13	-0.33	0.44	-0.67	-0.53
Property Plant And Equipment Net	0.46	0.33	0.13	-0.43	0.31	0.97	0.34	0.35	0.02	0.26	-0.15	0.36	0.32	0.47	-0.06		-0.14	0.53	0.15	0.12	0.22	0.16	0.67	-0.02	0.13	0.62
Retained Earnings	-0.23	-0.43	-0.44	-0.34	0.19	-0.26	0.04	-0.6	-0.71	0.18	0.77	-0.11	-0.2	0.18	-0.1	-0.14		0.27	0.12	-0.8	0.06	-0.03	-0.27	-0.57	0.04	0.29
Non Currrent Assets Other	-0.17	0.08	-0.14	-0.25	-0.09	0.45	-0.16	0.36	-0.28	0.15	0.51	0.05	-0.28	0.28	-0.22	0.53	0.27		0.12	-0.35	-0.01	0.07	0.77	-0.19	0.07	0.53
Common Stock Total Equity	0.48	-0.46	-0.07	-0.25	0.7	0.16	0.62	-0.14	-0.39	0.57	-0.13	0.56	0.49	0.59	-0.28	0.15	0.12	0.12		0.02	0.12	0.96	0.18	-0.47	0.52	0.48
Other Stockholder Equity	0.41	0.32	0.21	0.2	0.08	0.23	0.22	0.38	0.68	-0.07	-0.73	0.11	0.41	-0.13	0.27	0.12	-0.8	-0.35	0.02		-0.17	0.17	0.01	0.47	-0.06	-0.33
Short Term Debt	0.5	0.18	0.67	0.21	0.39	0.24	0.52	-0.27	-0.18	0.04	-0.22	0.39	0.5	0.46	-0.13	0.22	0.06	-0.01	0.12	-0.17		0.08	0.08	0.0	-0.03	0.04
Common Stock	0.56	-0.38	-0.05	-0.28	0.65	0.22	0.63	-0.02	-0.18	0.47	-0.24	0.45	0.57	0.47	-0.13	0.16	-0.03	0.07	0.96	0.17	0.08		0.16	-0.36	0.42	0.39
Accounts Payable	0.09	0.11	0.2	-0.06	-0.03	0.66	-0.04	0.53	-0.07	0.21	0.01	0.32	-0.04	0.4	-0.33	0.67	-0.27	0.77	0.18	0.01	0.08	0.16		0.08	0.24	0.51
Short Term Investments	0.06	0.5	0.32	0.08	-0.29	0.05	-0.14	0.22	0.66	-0.51	-0.28	-0.31	0.06	-0.44	0.44	-0.02	-0.57	-0.19	-0.47	0.47	0.0	-0.36	0.08		-0.31	-0.42
Other Assets	0.33	-0.34	-0.1	0.05	0.58	0.15	0.39	0.03	-0.59	0.81	-0.28	0.73	0.33	0.65	-0.67	0.13	0.04	0.07	0.52	-0.06	-0.03	0.42	0.24	-0.31		0.45
Other Liab	0.21	-0.15	-0.24	-0.47	0.37	0.56	0.25	0.11	-0.53	0.7	0.23	0.56	0.12	0.54	-0.53	0.62	0.29	0.53	0.48	-0.33	0.04	0.39	0.51	-0.42	0.45

Click cells to compare fundamentals

Protalix Biotherapeutics Account Relationship Matchups

Protalix Biotherapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	67.9M	73.7M	55.8M	84.4M	73.4M	52.1M
Other Current Liab	13.9M	15.2M	10.6M	15.3M	16.1M	16.9M
Total Current Liabilities	86.5M	33.2M	32.4M	45.5M	25.6M	20.5M
Net Debt	46.1M	(5.5M)	16.4M	2.6M	(14.2M)	(14.9M)
Cash	18.3M	39.0M	17.1M	23.6M	19.8M	31.4M
Non Current Assets Total	12.2M	12.0M	10.9M	14.5M	13.3M	9.8M
Cash And Short Term Investments	38.5M	39.0M	22.2M	44.6M	34.8M	33.8M
Net Receivables	2M	3.4M	4.6M	5.3M	2.9M	3.1M
Common Stock Shares Outstanding	29.1M	44.1M	48.5M	82.4M	81.1M	85.1M
Liabilities And Stockholders Equity	67.9M	73.7M	55.8M	84.4M	73.4M	52.1M
Non Current Liabilities Total	8.5M	46.5M	34.0M	5.3M	4.6M	4.4M
Other Current Assets	2.1M	1.3M	1.3M	1.1M	1.1M	1.6M
Total Liab	95.0M	79.7M	66.4M	50.9M	30.2M	55.3M
Total Current Assets	55.7M	61.7M	44.9M	69.9M	60.1M	43.3M
Short Long Term Debt Total	64.4M	33.5M	33.5M	26.3M	5.5M	5.2M
Total Stockholder Equity	(27.0M)	(6.0M)	(10.6M)	33.6M	43.2M	45.4M
Property Plant And Equipment Net	10.4M	9.9M	9.6M	10.9M	10.0M	10.5M
Retained Earnings	(347.4M)	(374.9M)	(389.9M)	(381.5M)	(378.4M)	(359.5M)
Non Currrent Assets Other	1.8M	2.1M	1.3M	528K	462K	438.9K
Other Stockholder Equity	320.3M	368.9M	379.2M	415.0M	421.5M	442.6M
Short Term Debt	59.9M	2.4M	2.2M	23.1M	1.5M	1.4M
Common Stock	35K	46K	54K	73K	76K	63.6K
Accounts Payable	7.2M	7.0M	5.9M	4.3M	4.5M	4.3M
Short Term Investments	20.3M	39.0M	5.1M	20.9M	15.1M	15.8M
Other Assets	7.4K	2.1M	1.3M	1.0	1.15	1.09
Other Liab	20.1M	4.0M	14.3M	1.6M	1.5M	1.4M
Property Plant Equipment	5.3M	10.4M	9.9M	9.6M	8.7M	8.1M
Current Deferred Revenue	5.4M	8.6M	13.2M	2.9M	3.3M	3.1M
Inventory	13.1M	18.0M	16.8M	19.0M	21.2M	22.3M
Net Tangible Assets	(70.3M)	(27.0M)	(6.0M)	(10.6M)	(9.6M)	(10.1M)
Long Term Debt	51.0M	51K	27.9M	28.2M	25.4M	28.8M
Capital Surpluse	270.5M	320.3M	368.9M	379.2M	436.0M	272.0M
Property Plant And Equipment Gross	10.4M	9.9M	9.6M	45.6M	45.8M	23.1M
Long Term Debt Total	51.5M	51K	27.9M	28.2M	25.4M	28.3M
Net Invested Capital	31.5M	21.9M	17.5M	53.8M	43.2M	23.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Protalix Stock Analysis

When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Protalix Historical Balance Sheet

Protalix Biotherapeutics Inventory

22.31 Million

About Protalix Balance Sheet Analysis

Protalix Biotherapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Non Current Assets Total

Cash And Short Term Investments

Protalix Biotherapeutics balance sheet Correlations

Protalix Biotherapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Protalix Biotherapeutics balance sheet Accounts

Also Currently Popular

Additional Tools for Protalix Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 0.99	Total Assets
Property Plant And Equipment Net	+ 0.97	Non Current Assets Total
Common Stock	+ 0.96	Common Stock Total Equity
Cash And Short Term Investments	+ 0.95	Cash
Total Current Assets	+ 0.95	Cash And Short Term Investments
Cash And Short Term Investments	+ 0.94	Total Assets

Other Stockholder Equity	- 0.8	Retained Earnings
Total Stockholder Equity	- 0.76	Total Liab
Other Stockholder Equity	- 0.73	Other Current Assets
Total Stockholder Equity	- 0.72	Non Current Liabilities Total
Retained Earnings	- 0.71	Common Stock Shares Outstanding
Other Assets	- 0.67	Total Stockholder Equity